Wellcome Sanger Institute

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann

Retrieved on: 
Monday, April 8, 2024
Royal, Medicine, FRS, Biochemical Society, Translational research, Wellcome Sanger Institute, Woman, Drug discovery, Trinity College, Royal Society, International, GSK, University, Membrane, Patient, Doctor of Philosophy, EMBO Gold Medal, University College London, Translation, Architecture, Therapy, Immune system, SAB, The Genetics Society, Molecular biology, Pharmaceutical industry

Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.

Key Points: 
  • Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.
  • During this time, she also collaborated with OMass’ co-founder, Professor Dame Carol Robinson, on unraveling the in vivo and in vitro assembly of soluble protein complexes.
  • Ali Jazayeri, Chief Scientific Officer at OMass Therapeutics, commented: “I look forward to working with Sarah.
  • Our previous long-standing collaboration on the assembly of soluble protein complexes demonstrates how her skillset can be complementary to our native mass spectrometry approach and can contribute to further developing our drug discovery platform.”
    Sarah Teichmann, Member of the Scientific Advisory Board of OMass Therapeutics, added: “I am thrilled to be joining OMass Therapeutics’ SAB.

Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer

Retrieved on: 
Wednesday, January 31, 2024
Health, Genetics, Health Technology, Research, Science, Biotechnology, Genomics, Oxford Nanopore Technologies, Growth, DNA, Gene, 3D, University, Database, Weill Cornell Medicine, CSO, Genome-wide association study, Master of Science, Wellcome Sanger Institute, GWAS, Algorithm, Molecular biology, Doctor of Philosophy, Antibiotics

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO).

Key Points: 
  • Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO).
  • Dan’s deep expertise in genomics technology development and commercialisation will be key to achieving the next phase of Enhanc3D Genomics’ growth.
  • Dr Hazel Jones, Chief Operating Officer and interim Chief Executive Officer, Enhanc3D Genomics, said: “Dan joins us at an exciting stage in the Company’s development as we begin to steer towards commercialisation.
  • I look forward to working alongside Dan as he joins the team.”
    Dr Dan Turner, Chief Scientific Officer, Enhanc3D Genomics, commented: “Enhanc3D Genomics has an exceptional reputation in the field of 3D genomics, and I’m delighted to take this opportunity to help drive the development of its technology further.

PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions

Retrieved on: 
Monday, January 15, 2024
Research, Animal, DNA, CBB, Atomic mass, Tree, Compatibility, Abraxis BioScience, Cell, Bacteria, High fidelity, Medical research, Plant, Fungus, Wellcome Sanger Institute, Blood

MENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit. This new offering expands the array of sample types suitable for long-read sequencing, including cells, bacteria, blood, tissue, plant nuclei, and insects.

Key Points: 
  • MENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit.
  • Nanobind kits are designed for researchers to efficiently extract high-quality, high molecular weight DNA across a wide range of sample types.
  • These kits are versatile, accommodating both manual (Nanobind PanDNA kit) and high-throughput (Nanobind CBB HT kit) settings.
  • "The new PanDNA kit will be the go-to kit for extracting DNA optimized for HiFi sequencing," said Jeff Eidel, Chief Commercial Officer at PacBio.

Element Announces Expanded Customer Base, New Products, and Unprecedented Capabilities on a Benchtop Sequencer

Retrieved on: 
Tuesday, January 9, 2024
Biology, RNA, Associate, JPM, Conference, Science, Protein, Wellcome Sanger Institute, Research, Pathology, CRISPR, DNA, Doctor of Philosophy, SAN, HD, Stanford University, Genetics, Computational biology, Trinity, Genome, Cell biology, Q50, Biological engineering, Tavarua, Pharmaceutical industry

Achieving the fastest growth rate since launch among its peers, Element generated revenues in excess of $25 million in 2023.

Key Points: 
  • Achieving the fastest growth rate since launch among its peers, Element generated revenues in excess of $25 million in 2023.
  • Element CEO and Co-founder Molly He presented on the following updates to AVITI at JPM:
    Expert mode HD – Enhanced output options.
  • An instrument option that allows users to generate 20 to 70 percent more reads per run from all sequencing kits.
  • "When we launched AVITI in 2022 we redefined what is possible on a benchtop sequencer, offering an unprecedented combination of accuracy, speed, and cost.

Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders

Retrieved on: 
Tuesday, November 28, 2023
Quotient, Agriculture, Therapy, Wellcome Sanger Institute, Flagship Pioneering, Office for Life Sciences, Culture, Ecosystem, USD, United, City, Senior advisor, University, Partnership, Innovation, Government, UK Government Decontamination Service, Flagship, Pharmaceutical industry, Airline, Science

CAMBRIDGE, Mass. and LONDON, Nov. 27, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.

Key Points: 
  • and LONDON, Nov. 27, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation.
  • The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.
  • Located in London, the new office will serve as a regional hub for Flagship's operations in the UK, and into Europe.
  • Flagship Pioneering creates and builds platform companies designed to generate multiple products that secure a healthier and more sustainable future.

Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders

Retrieved on: 
Tuesday, November 28, 2023
Quotient, Agriculture, Therapy, Wellcome Sanger Institute, Flagship Pioneering, Office for Life Sciences, Culture, Ecosystem, USD, United, City, Senior advisor, University, Partnership, Innovation, Government, UK Government Decontamination Service, Flagship, Pharmaceutical industry, Airline, Science

CAMBRIDGE, Mass. and LONDON, Nov. 28, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.

Key Points: 
  • and LONDON, Nov. 28, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation.
  • The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.
  • Located in London, the new office will serve as a regional hub for Flagship's operations in the UK, and into Europe.
  • Flagship Pioneering creates and builds platform companies designed to generate multiple products that secure a healthier and more sustainable future.

Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics

Retrieved on: 
Tuesday, November 21, 2023
Quotient, DNA, Senior, Entrepreneurship, Gene, Therapy, Genetic variation, Disease, Protein, Wellcome Sanger Institute, Flagship Pioneering, Data, Maltzahn, General partnership, Somatic genome processing, City, Health, Ageing, University, Neurodegenerative disease, MPH, Partnership, Flagship, Infection, Doctor of Philosophy, Cell, Biology, Immunodeficiency, Pharmaceutical industry, Vaccine, Genetics, MD

CAMBRIDGE, Mass., Nov. 21, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and modalities.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 21, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease.
  • "The assumption that we each have a single genome turns out to be off by a trillion-fold," said Geoffrey von Maltzahn, Ph.D., Co-Founder and Chief Executive Officer of Quotient Therapeutics and General Partner, Flagship Pioneering.
  • Jacob Rubens, Ph.D., Co-Founder and President of Quotient Therapeutics and Origination Partner, Flagship Pioneering added, "At Quotient, we're inspired by the maxim that 'Nothing in biology makes sense except in the light of evolution.'
  • Genetics has already created tremendous advances in human health, and Quotient is pioneering the next big leap forward."

Congenica and myTomorrows Announce Partnership to Advance Precision Oncology by Facilitating Rapid Access to Clinical Trials

Retrieved on: 
Wednesday, September 13, 2023
Cancer, Partnership, Physician, Patient, Wellcome Sanger Institute, Software, Pharmaceutical industry

The partnership between Congenica and myTomorrows will open new opportunities for physicians to search for access to pre-approval anti-cancer treatments and active clinical trials, specifically for patients whose cancers cannot be treated with approved treatment options.

Key Points: 
  • The partnership between Congenica and myTomorrows will open new opportunities for physicians to search for access to pre-approval anti-cancer treatments and active clinical trials, specifically for patients whose cancers cannot be treated with approved treatment options.
  • "We are thrilled to collaborate with myTomorrows to accelerate precision oncology and provide rapid access to clinical trials for patients facing limited treatment options," said Alistair Johnson, Chief Professional Services Officer at Congenica.
  • Commenting on the partnership, Michel van Harten, CEO at myTomorrows, stated, "Our partnership with Congenica reflects our shared commitment to connect tomorrow’s therapies to the people who need them today.
  • By collaborating on this initiative, we can expand the pool of eligible patients for precision oncology clinical trials and offer better access to individuals who may not have had access to these opportunities otherwise."

SKAN Research Trust and University of Cambridge to collaborate in Stem Cell Studies

Retrieved on: 
Wednesday, September 6, 2023
Wellcome–MRC Cambridge Stem Cell Institute, Partnership, University, Wellcome Sanger Institute, University of Cambridge, Biomedical Research, Research, DSM-IV codes, Regenerative medicine, CSCI, SKAN, Wellcome, Diagnosis, B cell, Pharmaceutical industry, Veterinary medicine

CAMBRIDGE, England and BENGALURU, India, Sept. 6, 2023 /PRNewswire/ -- SKAN Research Trust (SKAN), promoted by Indian entrepreneur Ashok Soota and the UK-based Wellcome-MRC Cambridge Stem Cell Institute (CSCI), is all set to bring to India cutting-edge expertise in stem cell research through a series of partnership agreements that were concluded today (6 September 2023) in Cambridge.

Key Points: 
  • CAMBRIDGE, England and BENGALURU, India, Sept. 6, 2023 /PRNewswire/ -- SKAN Research Trust (SKAN), promoted by Indian entrepreneur Ashok Soota and the UK-based Wellcome-MRC Cambridge Stem Cell Institute (CSCI), is all set to bring to India cutting-edge expertise in stem cell research through a series of partnership agreements that were concluded today (6 September 2023) in Cambridge.
  • CSCI and SKAN will jointly undertake specific research projects in stem cells and use their findings to improve the prevention, diagnosis, and treatment of diseases.
  • The agreements include the following:
    "I am hugely excited by SKAN's vision and confident that this new partnership with the Cambridge Stem Cell Institute will help catalyse exciting progress in biomedical research both in India and Cambridge," said Professor Bertie Göttgens, Director, Wellcome-MRC Cambridge Stem Cell Institute.
  • SKAN will upgrade its stem cell and bioinformatics capabilities including top-of-the-line sequencing technologies with concomitant cell culture methodologies.

SKAN Research Trust and University of Cambridge to collaborate in Stem Cell Studies

Retrieved on: 
Wednesday, September 6, 2023
Wellcome–MRC Cambridge Stem Cell Institute, Partnership, University, Wellcome Sanger Institute, University of Cambridge, Biomedical Research, Research, DSM-IV codes, Regenerative medicine, CSCI, SKAN, Wellcome, Diagnosis, B cell, Pharmaceutical industry, Veterinary medicine

CAMBRIDGE, England and BENGALURU, India, Sept. 6, 2023 /PRNewswire/ -- SKAN Research Trust (SKAN), promoted by Indian entrepreneur Ashok Soota and the UK-based Wellcome-MRC Cambridge Stem Cell Institute (CSCI), is all set to bring to India cutting-edge expertise in stem cell research through a series of partnership agreements that were concluded today (6 September 2023) in Cambridge.

Key Points: 
  • CAMBRIDGE, England and BENGALURU, India, Sept. 6, 2023 /PRNewswire/ -- SKAN Research Trust (SKAN), promoted by Indian entrepreneur Ashok Soota and the UK-based Wellcome-MRC Cambridge Stem Cell Institute (CSCI), is all set to bring to India cutting-edge expertise in stem cell research through a series of partnership agreements that were concluded today (6 September 2023) in Cambridge.
  • CSCI and SKAN will jointly undertake specific research projects in stem cells and use their findings to improve the prevention, diagnosis, and treatment of diseases.
  • The agreements include the following:
    "I am hugely excited by SKAN's vision and confident that this new partnership with the Cambridge Stem Cell Institute will help catalyse exciting progress in biomedical research both in India and Cambridge," said Professor Bertie Göttgens, Director, Wellcome-MRC Cambridge Stem Cell Institute.
  • SKAN will upgrade its stem cell and bioinformatics capabilities including top-of-the-line sequencing technologies with concomitant cell culture methodologies.